Biomedical Engineering Reference
In-Depth Information
d
n
4
y
3
n
g
|
8
Figure 7.9
(A) Synthesis of the siRNA-PEG conjugate and preparation of the
siRNA-PEG/PEI polyelectrolyte complex (PEC). (B) RT-PCR analysis
showing downregulation of VEGF mRNA in PC-3 cells by VEGF
siRNA-PEG/PEI PEC micelles: lane 1, no treatment; lane 2, VEGF
siRNA/PEI complexes; lane 3, VEGF siRNA-PEG/PEI PEC micelles;
lane 4, GFP siRNA/PEI complexes; lane 5, scrambled siRNA/PEI
complexes; lane 6, scrambled siRNA-PEG/PEI PEC micelles. (C)
Intratumoral VEGF mRNA transcript abundance level in PC-3 tumor
xenografts at day 3 after the last treatment of intratumoral injection of
VEGF siRNA-PEG/PEI PEC micelles. (D) Representative immuno-
histochemical staining of factor VIII antibody in PC-3 tumor xenografts
36 days after the initial injection for microvessel density assay. (E) Tumor
growth curves of PC-3 tumors; treatments were initiated when the
average tumor volume reached around 50 mm
3
. (Panels A, C, D, and E
adapted from Kim et al.
86
and panel B adapted from Kim et al.
107
, both
with permission from Elsevier.)
charged polyelectrolytes of siRNA and PEI, resulting in the formation of an
insoluble core. At the same time, the siRNA/PEI inner core was stabilized by
the PEG chains exposed on the surface.
108
The VEGF siRNA-PEG/PEI PEC
micelles showed greater stability than naked VEGF siRNA against enzymatic
